Popular on EntSun
- The World's No.1 Superstar Dies After Choking on a French Fry - 145
- NEMTAC Announces New Board of Directors Officers for 2024-2025 - 101
- One Dream, Three Amazing Journeys… On and Off the Basketball Court
- Vantiva Receives 2024 RDK "Distinguished Leader Award"
- FEM Provides a Safe, Free Space for Female Business Owners
- Diana Partners With OpsVeda To Leverage AI-ML To Get Closer To Its Consumers
- Immigrant Artists Explore Cultural, Historical and Social Experiences in "Unlocked Identities" Exhibition
- Human Resources Strategy Forum Celebrates 30 Years Empowering Leaders, Shaping the Next Generation of HR Innovators
- AVTECH Announces New Room Alert Bundles for Heat Safety and Enhanced Indoor Air Quality Monitoring
- "Monotheism and Devils" is the theologically dedicated sequel of "Prince of Eurasia" of the Islamic cleric and executive producer Prince Oak Oakleyski
Similar on EntSun
- MMCG Invest and Innowave Studio Merge to Revolutionize Feasibility Studies and Site Plans
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- eCaregivers Launches First-Ever Consumer-Driven Senior Care Platform for Private-Pay Home Care Offering Affordable, Full-Service Agency Experience
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- Superior Thin Film Solar Panel Advancements Open Great Opportunities in the Rapidly Developing Aerospace and Related Sectors: Stock Symbol: ASTI
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- Allegiant Management Group Launches New Website Following Recent Rebranding
- Quidax Launches $125,000 Crypto Innovation Pitch, Partners with Moonshot for TC Battlefield
Acquisition of Clinics Generating $100 Million to Complement Progress on Accelerated Drug Approval for Bipolar Depression NRx Pharmaceuticals: NRXP
EntSun News/11034720
NRXP: Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics.
MIAMI - EntSun -- NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
On August 26th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
More on EntSun News
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.
NRXP has formed partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality.
In March 2024 NRXP demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
NRXP presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
HOPE Therapeutics, is an NXRP subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRXP, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. With Hope ownership as an asset of NRXP, this will further strengthen the NRXP balance sheet and aims to further enhance shareholder value.
More on EntSun News
NRX-101 for Treatment of Chronic Pain:
In 2023, NRXP licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD.
During Q3 2023, NRXP tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRXP was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
Should NRX-101 succeed in clinical trials, NRXP will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
NRXP recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
Additionally, should NRXP or its partners succeed in serving 10% of the cUTI market, NRXP believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Potential Acquisition and Financing Agreements for $30 Million in Currently-Operating Interventional Psychiatry Clinics
On August 26th NRXP announced signing a non-binding Term Sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions), together with the signing of a Term Sheet for five currently operational clinics in the Western United States. In addition to the currently-signed non-binding Term Sheet, NRXP has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues in excess of $100 million. NRXP anticipates potential operations in the United States, France, and the United Kingdom.
More on EntSun News
- Campaign for Kindness: Floris UMC is bringing back respect, humility, and compassion this election season
- Situ Ve Offers a New Perspective on Love Amid the Rising Passport Bro Movement
- Sar Kamler Releases Debut Album: Butterfly: Colors of Armenian Duduk
- Pro Sound League: The Next Big Movement in Music Launching in 2025 – Join Us!
- Celebrate the Holidays with Free Flute and Guitar Concerts: "May Your Days Be Merry & Bright"
This non-dilutive acquisition funding is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange. Additional information to be presented by NRXP at upcoming HC Wainwright Annual Global Investment Conference in New York, September 9-11, 2024.
NRXP has formed partnerships to license clinical trial data from a French Government-funded trial and two NIH-funded trials all of which demonstrate efficacy of racemic Intravenous ketamine against depression and two of which demonstrate statistically significant benefit vs suicidality.
In March 2024 NRXP demonstrated the formulation of a pH neutral patentable form of IV ketamine that it anticipates will have widespread applicability both in treatment of depression and chronic pain.
NRXP presented final data from the recently completed phase 2b/3 trial of NRX-101 in suicidal bipolar depression4 at the American Society of Clinical Psychopharmacology's annual meeting. These data demonstrated a significantly improved safety profile versus the standard of care, as demonstrated by a clinically significant reduction in akathisia (P=0.025) and time to sustained remission from suicidality (P=0.05). Akathisia is an adverse event seen with antidepressant medications considered by many experts to be a precursor to suicide. Given the vital need for safer medications in this at-risk population, we plan to submit an NDA for Accelerated Approval to the US FDA for treatment of bipolar depression patients with suicidality or akathisia, based on these data as well as additional data from our STABIL-B5 trial.
HOPE Therapeutics, is an NXRP subsidiary that will focus on the delivery of advance psychiatric treatments, including ketamine-focused treatment for depression and suicidality. Unlike the core business of NRXP, that is focused on biotechnology Research and Development, HOPE is organized around consolidating existing best-in-class clinics into a nationwide network. This has been done previously and without much success with clinics that are not necessarily psychiatrist-led. With Hope ownership as an asset of NRXP, this will further strengthen the NRXP balance sheet and aims to further enhance shareholder value.
More on EntSun News
- Family Story Day Returns to El Paso
- Agency ends 3rd quarter with Welcoming 16 Hand Selected Influencers out of Thousands of Applicants
- Scout & Cellar Becomes First Winery in Texas to Receive B Corp Certification
- CRH Healthcare Acquires Four Urgent Care Clinics in Georgia
- Mezzo-Soprano Tracie Luck Returns to the Weinberg Center Stage
NRX-101 for Treatment of Chronic Pain:
In 2023, NRXP licensed US Patent 8,653,120 for the use of DCS in chronic pain and filed a now-accepted Investigational New Drug (IND) application with the FDA to initiate commercial drug development of NRX-101 in chronic pain. Data lock has now been achieved in a 200-person randomized prospective trial funded by the US DOD.
During Q3 2023, NRXP tested NRX-101 and its components against resistant pathogens that appear on the Congressionally mandated Qualified Infectious Disease Product (QIDP) list and proved in vitro effectiveness against antibiotic-resistant E. coli, Pseudomonas, and Acinetobacter. Accordingly, NRXP was granted QIDP designation, Fast Track Designation, and Priority Review by the US FDA in January 2024.
Should NRX-101 succeed in clinical trials, NRXP will consider developing a follow-on product that is anticipated to achieve another 20 years of patent exclusivity.
NRXP recently announced data demonstrating that NRX-101 does not compromise the intestinal microbiome, unlike common antibiotics including Clindamycin and Ciprofloxacin. Should these findings be documented in human patients, NRX-101 would represent the only treatment for cUTI that does not cause C. Difficile infection.
Additionally, should NRXP or its partners succeed in serving 10% of the cUTI market, NRXP believes that the revenue from NRX-101 has the potential to be hundreds of million annually, based on 3 million cases per year in the US and potential pricing of over $3,500/course of therapy.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com/
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on EntSun News
- IGC Pharma Wins 2 Awards in Phase 1 of NIA's AI PREPARE Challenge, Advancing Alzheimer's Early Prediction Research
- Sixx Pack Krew (SPK): Atlanta's Rising Collective in Music, Gaming, and Influence
- Renowned Beauty Brand 'Natalia Megan Beauty' Unveils Latest Product Additions
- Get in the Halloween Spirit at Rare Books LA Union Station
- Solution Tavern Opens Bringing Drinks, Sports, Trivia, and More to Local Neighborhood!
- Parler Unveils PlayTV: A New Playground for Content Creators!
- Arena Rock Tribute Will Rock Turning Stone - Final Show
- Indie Gospel Recording Artist Dianna Hobbs Signs with Halo Management and Releases New Single 'Don't Know Why'—OUT NOW
- Superior Thin Film Solar Panel Advancements Open Great Opportunities in the Rapidly Developing Aerospace and Related Sectors: Stock Symbol: ASTI
- Grand opening of the ResC4EU platform to support companies withstanding supply chain disruptions
- Vertical Horizon Celebrates 25 Years of "Everything You Want" at the Weinberg Center
- New Study Reveals Alarming Cardiac Risks Associated with Electroshock Treatment
- Columbus Fashion Council Announces Bruce & Glen Proctor as Headline Designer for Finale Runway Show
- "Live Courageously" With Host John Duffy will Have Guest Tom Ohmer an Actor From the Stage and TV
- The Ultimate Guide to Buying Historic Luxury Homes in Winter Park, FL Now Available
- And The Winner Is: Special Request Ft Rey T (AKA) Reynard Thomas
- Sky Lites Drone Shows with LASERs
- Don Barnhart Set to Bring the Laughter to Delirious Comedy Club In Downtown Las Vegas
- Junetini to Host 'Meet, Greet & Tasting' at the Ultimate Women's Expo 2024
- Allegiant Management Group Launches New Website Following Recent Rebranding